Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RapMed-2304
- Development stage
- Preclinical
- Lead developer
- RAPHAS
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Percutaneous
01
Overview
RapMed-2304 is a development code used by RAPHAS for two distinct microneedle patch programs. The primary program is a prescription (Rx) therapeutic for the treatment of migraine, which utilizes the small molecule naratriptan, a serotonin 5-HT1 receptor agonist. This formulation is designed for percutaneous delivery using RAPHAS's proprietary Droplet-born Air Blowing (DAB) technology, which aims to improve bioavailability and patient compliance compared to traditional oral triptans. A second program under the same code is an over-the-counter (OTC) product for acne in the Japanese market. Both programs are currently in the preclinical stage of development.
- Other names
- Migraine Rxnaratriptan microneedle patch
02
Targets
5-HT1R (5-HT1 receptor family)
Beyond the preview
Go deeper on RapMed-2304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RapMed-2304.